Eptinezumab-jjmr (Vyepti)

Vyepti (eptinezumab‑jjmr) is covered for migraine prevention in adults ≥18 with ≥4 migraine days/month at doses up to 300 mg IV every 3 months with 12‑month authorizations; patients not meeting these criteria (e.g., <18 years, <4 migraine days/month) are excluded. Coverage requires documentation of trials of at least two different classes of standard prophylactic therapies with inadequate efficacy or intolerable adverse events, plus either a trial of ≥1 triptan (or documented triptan contraindication), or documented benefit if already on Vyepti, or a switch from another CGRP inhibitor, with supporting documentation of diagnosis, baseline frequency, prior therapies, and dosing plan.

"Prevention of migraine headaches in adults"

Sign up to see full coverage criteria, indications, and limitations.